Cover Image
市場調查報告書

視力保健:醫療設備的開發平台評估

Vision Care Devices - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 350916
出版日期 內容資訊 英文 342 Pages
訂單完成後即時交付
價格
Back to Top
視力保健:醫療設備的開發平台評估 Vision Care Devices - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月11日 內容資訊: 英文 342 Pages
簡介

本報告提供視力保健的開發中產品調查分析,以各開發階段比較分析為焦點,提供您正在開發開發中產品的主要企業,進行中的臨床試驗相關資訊等系統性資訊。

第1章 目錄

第2章 簡介

  • 視力保健概要

第3章 開發中的產品

  • 視力保健 - 開發中產品:各開發階段
  • 視力保健 - 開發中產品:各市場區隔
  • 視力保健 - 開發中產品:各地區
  • 視力保健 - 開發中產品:法規別
  • 視力保健 - 開發中產品:核准預定日別
  • 視力保健 - 進行中的臨床試驗

第4章 視力保健 - 正在開發的開發中產品:各企業

  • 視力保健企業 - 開發中產品:各開發階段
  • 視力保健 - 開發中產品:各開發階段

第5章 視力保健企業與產品概要

  • Adventus Technology Inc
  • Alcon, Inc.
  • Apeliotus Ophthalmics
  • Auburn University
  • Axcelon Biopolymers Corp.
  • Bar-Ilan University
  • Bausch & Lomb Incorporated
  • Belfanti - Fureder - Meidl technisches Buro f Elektro u Haustechnik GmbH
  • Bionic Vision Australia
  • Body Organ Biomedical Corp.
  • Children's Hospital Boston
  • Consejo Superior de Investigaciones Cientificas
  • CooperVision, Inc.
  • Cornell University
  • EP Global Communications, Inc.
  • eSight Corporation
  • Euclid Systems Corporation
  • Eyegenix
  • EyeNetra, Inc.
  • Eyenovations等

第6章 視力保健 - 最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0483EPD

GlobalData's Medical Devices sector report, "Vision Care Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Vision Care Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vision Care Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Vision Care Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vision Care Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vision Care Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 15

2 Introduction 16

  • 2.1 Vision Care Devices Overview 16

3 Products under Development 18

  • 3.1 Vision Care Devices - Pipeline Products by Stage of Development 18
  • 3.2 Vision Care Devices - Pipeline Products by Segment 19
  • 3.3 Vision Care Devices - Pipeline Products by Territory 20
  • 3.4 Vision Care Devices - Pipeline Products by Regulatory Path 21
  • 3.5 Vision Care Devices - Pipeline Products by Estimated Approval Date 22
  • 3.6 Vision Care Devices - Ongoing Clinical Trials 23

4 Vision Care Devices - Pipeline Products under Development by Companies 24

  • 4.1 Vision Care Devices Companies - Pipeline Products by Stage of Development 24
  • 4.2 Vision Care Devices - Pipeline Products by Stage of Development 27

5 Vision Care Devices Companies and Product Overview 31

  • 5.1 Acuity Polymers Inc Company Overview 31
  • 5.2 Adventus Technology Inc Company Overview 33
  • 5.3 Aeon Astron Corporation Company Overview 34
  • 5.4 Alcon Laboratories Inc Company Overview 36
  • 5.5 Allotex Inc Company Overview 44
  • 5.6 Apeliotus Ophthalmics (Inactive) Company Overview 45
  • 5.7 Auburn University Company Overview 47
  • 5.8 Axcelon Biopolymers Corp. Company Overview 48
  • 5.9 Bar-Ilan University Company Overview 49
  • 5.10 Bausch & Lomb Inc Company Overview 51
  • 5.11 Bionic Sight LLC Company Overview 55
  • 5.12 Bionic Vision Australia Company Overview 56
  • 5.13 Bionode LLC Company Overview 60
  • 5.14 Children's Hospital Boston Company Overview 61
  • 5.15 Consejo Superior de Investigaciones Cientificas Company Overview 62
  • 5.16 CooperVision Inc Company Overview 63
  • 5.17 Cornea Biosciences Company Overview 68
  • 5.18 DeepOptics Company Overview 69
  • 5.19 eSight Corp Company Overview 70
  • 5.20 Euclid Systems Corp Company Overview 71
  • 5.21 e-Vision Medical Devices, Inc. Company Overview 72
  • 5.22 Eyenovations Company Overview 74
  • 5.23 EyeYon Medical Company Overview 75
  • 5.24 Forschungszentrum Julich GmbH Company Overview 77
  • 5.25 iBionics Inc Company Overview 78
  • 5.26 Imperial College London Company Overview 79
  • 5.27 Institute of Photonic Sciences Company Overview 80
  • 5.28 iSTAR Medical SA Company Overview 81
  • 5.29 John Hopkins University Company Overview 82
  • 5.30 Johnson & Johnson Vision Care Inc Company Overview 83
  • 5.31 Massachusetts Eye and Ear Infirmary Company Overview 85
  • 5.32 McGill University Company Overview 86
  • 5.33 Mercy Research and Development Company Overview 87
  • 5.34 Meta Biomed Co Ltd Company Overview 89
  • 5.35 Microbiosensor Ltd Company Overview 90
  • 5.36 Monash University Company Overview 91
  • 5.37 Nano Retina, Inc. Company Overview 92
  • 5.38 Novartis AG Company Overview 93
  • 5.39 Ocular Dynamics, LLC Company Overview 94
  • 5.40 Ocutec Ltd Company Overview 95
  • 5.41 OPIA Technologies SAS Company Overview 96
  • 5.42 Oxsight Ltd Company Overview 98
  • 5.43 PixelOptics Inc Company Overview 99
  • 5.44 Pixium Vision Company Overview 100
  • 5.45 Presbia Plc Company Overview 106
  • 5.46 Queensland University of Technology Company Overview 110
  • 5.47 Refocus Group Inc Company Overview 111
  • 5.48 RetMap Inc Company Overview 114
  • 5.49 ReVision Optics Inc Company Overview 115
  • 5.50 Royal College of Surgeons in Ireland Company Overview 118
  • 5.51 Stanford University Company Overview 119
  • 5.52 Studio Oculistico Gualdi Company Overview 121
  • 5.53 SynergEyes Inc Company Overview 122
  • 5.54 Tel Aviv University Company Overview 124
  • 5.55 The University of New South Wales Company Overview 125
  • 5.56 The Wilmer Eye Institute at Johns Hopkins Company Overview 126
  • 5.57 UltraVision CLPL Company Overview 127
  • 5.58 University of Auckland Company Overview 128
  • 5.59 University of California Irvine Company Overview 129
  • 5.60 University of California San Diego Company Overview 130
  • 5.61 University of Chicago Medical Center Company Overview 133
  • 5.62 University of Florida Company Overview 134
  • 5.63 University of Illinois at Chicago Company Overview 135
  • 5.64 University of Oxford Company Overview 137
  • 5.65 University of South Florida Company Overview 139
  • 5.66 University of Tennessee Company Overview 140
  • 5.67 University of Tubingen Company Overview 141
  • 5.68 University of Valencia Company Overview 142
  • 5.69 University of Washington Company Overview 144
  • 5.70 Valeant Pharmaceuticals International Inc Company Overview 146
  • 5.71 Va-st Ltd Company Overview 159
  • 5.72 Visioneering Technologies Inc Company Overview 160
  • 5.73 VISTAKON Pharmaceuticals LLC Company Overview 164
  • 5.74 Visus Technology Inc Company Overview 165
  • 5.75 Weill Cornell Medical College Company Overview 166
  • 5.76 Western University Company Overview 168
  • 5.77 Yolia Health Company Overview 169
  • 5.78 ZircLight Inc. Company Overview 170

6 Vision Care Devices - Recent Developments 172

  • 6.1 Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 172
  • 6.2 Sep 12, 2017: eSight 3 Launches in Australia and New Zealand 172
  • 6.3 Sep 12, 2017: Essilor Of America Unveils Three Innovative Lens Technologies With The Ultimate Lens Package 172
  • 6.4 Sep 11, 2017: New Data Shows DAILIES TOTAL1 Multifocal Contact Lenses Are Comfortable and Less Dry at the End of the Day 174
  • 6.5 Sep 11, 2017: New Data Shows DAILIES TOTAL1 Multifocal Contact Lenses Are Comfortable and Less Dry at the End of the Day 175
  • 6.6 Sep 08, 2017: Essilor is Gold Sponsor of the 2 nd World Congress of Optometry 176
  • 6.7 Sep 07, 2017: Industry Leader Dr. Doug Benoit Joins VTI as Executive Director of Professional Affairs 176
  • 6.8 Sep 06, 2017: ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance 177
  • 6.9 Sep 06, 2017: Optometrist Chooses the KAMRA Corneal Inlay for Her Solution to Reading Glasses 178
  • 6.10 Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 179
  • 6.11 Aug 31, 2017: The Cooper Companies Announces Third Quarter 2017 Results 180
  • 6.12 Aug 30, 2017: Alcon revamps the packaging for its AIR OPTIX brand monthly replacement contact lenses 181
  • 6.13 Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 181
  • 6.14 Aug 15, 2017: World's fastest growing IOL Company - Opens Second Manufacturing Facility in Thailand 182
  • 6.15 Aug 14, 2017: TearLab Reports Second Quarter and First Half 2017 Financial Results 183
  • 6.16 Aug 10, 2017: NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results 184
  • 6.17 Aug 09, 2017: Bausch + Lomb Receives 510(K) Clearance From FDA for the Therapeutic use of Boston XO Materials 185
  • 6.18 Aug 09, 2017: Bausch + Lomb Receives 510(K) Clearance From FDA for the Therapeutic use of Boston XO2 Materials 186
  • 6.19 Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 187
  • 6.20 Aug 02, 2017: STAAR Surgical Reports Second Quarter 2017 Results 190
  • 6.21 Aug 02, 2017: Essilor wins Sustainable Business Award for its commitment to the United Nation's Sustainable Development Goals 191
  • 6.22 Aug 01, 2017: Visioneering Technologies Announces Lynn Cali-Cianci As Executive Territory Manager, New York City/Long Island 191
  • 6.23 Jul 28, 2017: Essilor International: Resilient First Half 192
  • 6.24 Jul 28, 2017: Topcon: Notice of Changes of Executive Officers 196
  • 6.25 Jul 27, 2017: Pixium Vision Announces H1 2017 Financial Results and Provides an Update on Its Activities 197
  • 6.26 Jul 27, 2017: Hoya Reports First Quarter Financial Results 199
  • 6.27 Jul 25, 2017: Visioneering Technologies Appoints Lisa Humble as Senior Territory Manager For North and South Carolina 199
  • 6.28 Jul 24, 2017: Antitrust process update for the proposed combination between Essilor and Luxottica 200
  • 6.29 Jul 21, 2017: Sikka Software Wins API World 2017 Award for Health API, Leads the Way in Retail Healthcare Innovation 200
  • 6.30 Jul 20, 2017: Dr. Jim Raulino Joins the VTI Team as Executive Territory Manager for Sacramento and Reno 201
  • 6.31 Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 201
  • 6.32 Jul 18, 2017: Visioneering Technologies Appoints Gary Sacks as Executive Territory Manager For New York/Western Massachusetts 207
  • 6.33 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 207
  • 6.34 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 208
  • 6.35 Jul 10, 2017: NovaBay Pharmaceuticals Announces CFO Transition 208
  • 6.36 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 209
  • 6.37 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 210

7 Appendix 337

  • 7.1 Methodology 337
  • 7.2 About GlobalData 340
  • 7.3 Contact Us 340
  • 7.4 Disclaimer 340

List of Tables

1.1 List of Tables

  • Table 1: Vision Care Devices - Pipeline Products by Stage of Development 20
  • Table 2: Vision Care Devices - Pipeline Products by Segment 21
  • Table 3: Vision Care Devices - Pipeline Products by Territory 22
  • Table 4: Vision Care Devices - Pipeline Products by Regulatory Path 23
  • Table 5: Vision Care Devices - Pipeline Products by Estimated Approval Date 24
  • Table 6: Vision Care Devices - Ongoing Clinical Trials 25
  • Table 7: Vision Care Devices Companies - Pipeline Products by Stage of Development 26
  • Table 8: Vision Care Devices - Pipeline Products by Stage of Development 29
  • Table 9: Acuity Polymers Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 10: Acuity 58 - Product Status 33
  • Table 11: Acuity 58 - Product Description 33
  • Table 12: Acuity 85 - Product Status 34
  • Table 13: Acuity 85 - Product Description 34
  • Table 14: Adventus Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 15: Corneal Onlay - Product Status 35
  • Table 16: Corneal Onlay - Product Description 35
  • Table 17: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 18: Biolens - Product Status 36
  • Table 19: Biolens - Product Description 36
  • Table 20: Contact Lens - Product Status 37
  • Table 21: Contact Lens - Product Description 37
  • Table 22: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 23: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 38
  • Table 24: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 39
  • Table 25: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status 39
  • Table 26: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description 39
  • Table 27: Dailies Total 1 Colors SiHy Lens - Product Status 40
  • Table 28: Dailies Total 1 Colors SiHy Lens - Product Description 40
  • Table 29: Dailies Total 1 Toric SiHy Lens - Product Status 40
  • Table 30: Dailies Total 1 Toric SiHy Lens - Product Description 40
  • Table 31: Smart Contact Lens - Diabetes - Product Status 41
  • Table 32: Smart Contact Lens - Diabetes - Product Description 41
  • Table 33: Weekly WG SiHy Lens - Product Status 41
  • Table 34: Weekly WG SiHy Lens - Product Description 42
  • Table 35: Alcon Laboratories Inc - Ongoing Clinical Trials Overview 43
  • Table 36: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 44
  • Table 37: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 45
  • Table 38: Allotex Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 39: Allotex Natural Allograft Lens - Product Status 46
  • Table 40: Allotex Natural Allograft Lens - Product Description 46
  • Table 41: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 42: Comfort Lens - Product Status 47
  • Table 43: Comfort Lens - Product Description 47
  • Table 44: Contact Lens - Glaucoma - Product Status 48
  • Table 45: Contact Lens - Glaucoma - Product Description 48
  • Table 46: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 47: Smart Contact Lenses - Product Status 49
  • Table 48: Smart Contact Lenses - Product Description 49
  • Table 49: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 50: MC - PHEMA Based Contact Lens - Product Status 50
  • Table 51: MC - PHEMA Based Contact Lens - Product Description 50
  • Table 52: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 53: Bionic Contact Lens - Product Status 51
  • Table 54: Bionic Contact Lens - Product Description 51
  • Table 55: Vision Substitution Device - Product Status 52
  • Table 56: Vision Substitution Device - Product Description 52
  • Table 57: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 58: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status 53
  • Table 59: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description 54
  • Table 60: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status 54
  • Table 61: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description 55
  • Table 62: Ultra Plus Powers Lens - Product Status 55
  • Table 63: Ultra Plus Powers Lens - Product Description 56
  • Table 64: Ultra Toric Lens - Product Status 56
  • Table 65: Ultra Toric Lens - Product Description 56
  • Table 66: Bionic Sight LLC Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 67: Neuro-Prosthetic Device - Product Status 57
  • Table 68: Neuro-Prosthetic Device - Product Description 57
  • Table 69: Bionic Vision Australia Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 70: High-Acuity Device With 1024 Electrodes - Product Status 58
  • Table 71: High-Acuity Device With 1024 Electrodes - Product Description 58
  • Table 72: High-Acuity Device With 256 Electrodes - Product Status 59
  • Table 73: High-Acuity Device With 256 Electrodes - Product Description 59
  • Table 74: Wide-View Device With 24-channel - Product Status 59
  • Table 75: Wide-View Device With 24-channel - Product Description 60
  • Table 76: Wide-View Device With 44-channel - Product Status 60
  • Table 77: Wide-View Device With 44-channel - Product Description 60
  • Table 78: Wide-View Device With 98 Electrodes - Product Status 61
  • Table 79: Wide-View Device With 98 Electrodes - Product Description 61
  • Table 80: Bionode LLC Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 81: Contact Lenses - Product Status 62
  • Table 82: Contact Lenses - Product Description 62
  • Table 83: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 84: Contact Lens Drug Delivery Device - Product Status 63
  • Table 85: Contact Lens Drug Delivery Device - Product Description 63
  • Table 86: Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 87: Reduced Optical Instrument - Product Status 64
  • Table 88: Reduced Optical Instrument - Product Description 64
  • Table 89: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 90: Biofinity Energys - Product Status 65
  • Table 91: Biofinity Energys - Product Description 65
  • Table 92: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 66
  • Table 93: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 66
  • Table 94: SiH Multifocal - Product Status 66
  • Table 95: SiH Multifocal - Product Description 67
  • Table 96: CooperVision Inc - Ongoing Clinical Trials Overview 68
  • Table 97: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 69
  • Table 98: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 69
  • Table 99: Cornea Biosciences Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 100: Bioengineered Cornea - Product Status 70
  • Table 101: Bioengineered Cornea - Product Description 70
  • Table 102: DeepOptics Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 103: Omnifocal Adaptive Lens - Product Status 71
  • Table 104: Omnifocal Adaptive Lens - Product Description 71
  • Table 105: eSight Corp Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 106: evSpex - Product Status 72
  • Table 107: evSpex - Product Description 72
  • Table 108: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 109: Drug-Eluting Contact Lenses - Product Status 73
  • Table 110: Drug-Eluting Contact Lenses - Product Description 73
  • Table 111: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 112: Electronic Contact Lens - Product Status 74
  • Table 113: Electronic Contact Lens - Product Description 74
  • Table 114: Electronic Focusing Eyeglasses - Product Status 75
  • Table 115: Electronic Focusing Eyeglasses - Product Description 75
  • Table 116: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 117: Drug Dispensing Contact Lens - Product Status 76
  • Table 118: Drug Dispensing Contact Lens - Product Description 76
  • Table 119: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 120: DSPEK - Product Status 77
  • Table 121: DSPEK - Product Description 77
  • Table 122: Hyper-CL - Drug Delivery - Product Status 78
  • Table 123: Hyper-CL - Drug Delivery - Product Description 78
  • Table 124: Forschungszentrum Julich GmbH Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 125: Retinal Electrode - Product Status 79
  • Table 126: Retinal Electrode - Product Description 79
  • Table 127: iBionics Inc Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 128: iBIONICS Diamond Eye - Product Status 80
  • Table 129: iBIONICS Diamond Eye - Product Description 80
  • Table 130: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 131: Contact Lens - Product Status 81
  • Table 132: Contact Lens - Product Description 81
  • Table 133: Institute of Photonic Sciences Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 134: SMARTLENS - Product Status 82
  • Table 135: SMARTLENS - Product Description 82
  • Table 136: iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 137: STARvue - Product Status 83
  • Table 138: STARvue - Product Description 83
  • Table 139: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 84
  • Table 140: Intra-corneal Implant - Product Status 84
  • Table 141: Intra-corneal Implant - Product Description 84
  • Table 142: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 143: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 85
  • Table 144: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 85
  • Table 145: Anti-allergic Contact Lens - Product Status 86
  • Table 146: Anti-allergic Contact Lens - Product Description 86
  • Table 147: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 87
  • Table 148: Therapeutic Contact Lens - Product Status 87
  • Table 149: Therapeutic Contact Lens - Product Description 87
  • Table 150: McGill University Pipeline Products & Ongoing Clinical Trials Overview 88
  • Table 151: Portable System - Amblyopia - Product Status 88
  • Table 152: Portable System - Amblyopia - Product Description 88
  • Table 153: Mercy Research and Development Pipeline Products & Ongoing Clinical Trials Overview 89
  • Table 154: First Aid Lens - Product Status 89
  • Table 155: First Aid Lens - Product Description 89
  • Table 156: Healing Lens - Product Status 90
  • Table 157: Healing Lens - Product Description 90
  • Table 158: Meta Biomed Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 91
  • Table 159: Artificial Cornea - Product Status 91
  • Table 160: Artificial Cornea - Product Description 91

List of Figures

1.2 List of Figures

  • Figure 1: Vision Care Devices - Pipeline Products by Stage of Development 20
  • Figure 2: Vision Care Devices - Pipeline Products by Segment 21
  • Figure 3: Vision Care Devices - Pipeline Products by Territory 22
  • Figure 4: Vision Care Devices - Pipeline Products by Regulatory Path 23
  • Figure 5: Vision Care Devices - Pipeline Products by Estimated Approval Date 24
  • Figure 6: Vision Care Devices - Ongoing Clinical Trials 25
Back to Top